(Reuters) - Data presented on Saturday at the American Society of Clinical Oncology annual meeting in Chicago found Erbitux patients lived an average of 10.1 months, while those who received only the chemotherapy regimen had a median overall survival of 7.4 months, researchers said.
The survival difference of 2.7 months was considered to be statistically significant.
Read more at Reuters.com Government Filings News
The survival difference of 2.7 months was considered to be statistically significant.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment